Rheumatology Medical Billing Services

What Makes Rheumatology Billing Uniquely Demanding

Rheumatology combines three of the hardest things in medical billing: expensive biologic drugs, in-office infusion services, and complex chronic-disease E/M — all under payers that demand step therapy documentation and prior authorization for nearly everything that matters. A single infliximab infusion can put four figures of drug cost on your books before the payer decides whether to honor it. Rheumatology billing services that treat this like generic office billing will bleed a practice dry; here's how we handle the parts that decide profitability.

Biologics and Buy-and-Bill: Where the Real Money Sits

In-office biologics (infliximab, rituximab, abatacept, tocilizumab) run on the buy-and-bill model — the practice purchases the drug, administers it, and bills the payer J-code plus administration. The margin is real but so is the exposure: one denied infusion can erase the profit of ten paid ones. We verify benefits and authorization before every single infusion, confirm the payer's preferred drug and site-of-care rules, track units against the auth, and bill drug wastage correctly with the JW/JZ modifiers Medicare requires. Nothing gets infused that hasn't been cleared for payment.

Infusion and Injection Coding Done Right

Infusion billing is time-based and hierarchical: the initial administration code, additional-hour add-ons, and sequential or concurrent drug administrations each follow strict rules, and the documented start and stop times decide what you may bill. Subcutaneous biologics, therapeutic injections, and ultrasound-guided joint injections (with their own guidance codes and laterality modifiers) each have their own edit patterns. Our coders work from the nursing infusion record — not assumptions — so administration revenue is complete and audit-proof.

Prior Authorization and Step Therapy

Every biologic needs prior authorization, and most payers enforce step therapy: documented failure of conventional DMARDs like methotrexate before a biologic is approved. Denials here are rarely about the medicine and almost always about the paperwork — missing trial dates, undocumented intolerance, or an expired auth on a maintenance infusion. We maintain an authorization calendar for every infusion patient, renew before expiration, and build step-therapy histories into every request so approvals come through the first time.

Chronic-Care E/M That Reflects the Work

Rheumatologists manage some of the most complex chronic patients in medicine, and the E/M coding should reflect it — high-complexity medical decision-making, prolonged services when documented, and split billing when an infusion visit includes a genuinely separate evaluation (modifier 25, with documentation that stands alone). Undercoding is endemic in rheumatology; practices routinely leave a level of E/M on the table visit after visit out of audit fear. We code what the documentation supports — no more, and no less.

The Denial Patterns We Watch For

Rheumatology denials cluster predictably: medical necessity on biologics (step therapy gaps), authorization expirations on maintenance schedules, infusion time documentation, frequency limits on labs and DEXA scans, and diagnosis specificity for drugs approved only for certain indications. Our team tracks every denial by pattern and closes the upstream gap — see our denial code library for how we work each type, and our rheumatology billing guide for the full specialty playbook.

What Our Rheumatology Medical Billing Services Include

Complete rheumatology RCM: benefits verification and biologic prior authorization with step-therapy documentation, infusion suite coding from nursing records, J-code and wastage billing, chronic-care E/M coding review, denial management with payer-specific appeal criteria, and monthly reporting that shows drug margin — not just collections — so you know whether your infusion suite is actually profitable. Free one-week claims audit for new practices.